Scotiabank Initiates Coverage On Rocket Pharmaceuticals with Sector Outperform Rating, Announces Price Target of $50

Benzinga · 10/16 14:15
Scotiabank analyst Greg Harrison initiates coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) with a Sector Outperform rating and announces Price Target of $50.